On Feb. 17, 2021, Immunic announced that its lead asset, IMU-838, the company’s selective oral DHODH inhibitor, had shown evidence of clinical activity in hospitalized patients with moderate coronavirus disease 2019 (COVID-19).

This planned main analysis of the company’s phase 2 CALVID-1 trial was based on data from 204 randomized patients and includes top-line clinical efficacy, safety, disease marker, and virology data. A final analysis of the complete randomized patient population of 223, which comprise data on all endpoints, including subgroup and sensitivity analyses, was expected to be available in the second quarter of 2021.